Alembic Pharma
Ticker >

Alembic Pharma share price

Alembic Pharmaceuticals Ltd.

NSE: APLLTD BSE: 533573 SECTOR: Pharmaceuticals & Drugs  134k   919   152

997.50
+39.50 (4.12%)
NSE: 25 Apr 04:05 PM

Price Summary

Today's High

₹ 1010

Today's Low

₹ 955.8

52 Week High

₹ 1094

52 Week Low

₹ 542.4

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 19607.17 Cr.

Enterprise Value

₹ 20213.78 Cr.

No. of Shares

19.66 Cr.

P/E

32.95

P/B

4.15

Face Value

₹ 2

Div. Yield

0.8 %

Book Value (TTM)

₹  240.1

CASH

₹ 28.46 Cr.

DEBT

₹ 635.07 Cr.

Promoter Holding

69.61 %

EPS (TTM)

₹  30.28

Sales Growth

2.26%

ROE

7.15 %

ROCE

7.2%

Profit Growth

-36.21 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alembic Pharmaceuticals Ltd.

Azithral TELLZY ZEET Elena Corazon MEGACARE ZENOM CORIUM GASTRON ENTERON Maxis Ouron

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.26%
3 Year7.61%
5 Year11.82%

Profit Growth

1 Year-36.21%
3 Year-29.02%
5 Year-3.85%

ROE%

1 Year7.15%
3 Year14.52%
5 Year20.1%

ROCE %

1 Year7.2%
3 Year14.77%
5 Year19.01%

Debt/Equity

0.1439

Price to Cash Flow

26.85

Interest Cover Ratio

8.06

CFO/PAT (5 Yr. Avg.)

1.12477049304401

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 69.61 0
Dec 2023 69.61 0
Sep 2023 69.61 0
Jun 2023 69.61 0
Mar 2023 69.61 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 8.06.
  • The Company has been maintaining an effective average operating margins of 22.371578759547% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 44.122144063028 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.12477049304401.
  • The company has a high promoter holding of 69.61%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 20.9052154994598.

 Limitations

  • The company has shown a poor profit growth of -29.0156186955793% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.60544710548643% for the Past 3 years.
  • Tax rate is low at -0.228363299994219.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 1310.21 1307.12 1332.27 1478.84 1588.39
Total Expenditure 1085.99 1137.94 1166.55 1271.38 1251.25
Operating Profit 224.22 169.18 165.72 207.46 337.14
Other Income 0.59 1.96 11.84 8.95 3.3
Interest 14.65 13.59 14.29 15.39 14.66
Depreciation 65.85 73.54 65.75 67.18 69.08
Exceptional Items 0 0 0 0 0
Profit Before Tax 144.31 84.01 97.52 133.84 256.7
Tax 25.18 -46.53 0 0 23.46
Profit After Tax 119.13 130.54 97.52 133.84 233.24
Adjusted EPS (Rs) 6.06 6.64 4.96 6.81 11.87

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 3660.28 4132.56 5066.88 5035.4 5149
Total Expenditure 2800.98 2940.87 3617.71 4126.63 4484.96
Operating Profit 859.3 1191.69 1449.17 908.77 664.04
Other Income 25.79 145.96 84.08 51.17 3.85
Interest 14.87 25.19 12.98 17.02 49
Depreciation 105.59 135.67 182.53 284.92 272.95
Exceptional Items 0 -10 0 0 0
Profit Before Tax 764.63 1166.79 1337.74 658 345.94
Tax 153.42 197.39 241.2 114.45 -0.79
Net Profit 611.21 969.4 1096.54 543.55 346.73
Adjusted EPS (Rs.) 32.42 51.43 55.79 27.65 17.64

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 37.7 37.7 39.31 39.31 39.31
Total Reserves 2674.71 3308.32 5062.5 5251.03 4374.98
Borrowings 499.3 886.99 199.89 0 0
Other N/C liabilities 96.58 192.26 203.19 204.25 86.67
Current liabilities 1397.76 1649.99 1378.36 1694.45 1551.3
Total Liabilities 4706.05 6075.26 6883.25 7189.04 6052.26
Assets
Net Block 1077.09 1268.11 1773.82 1771.1 2377.47
Capital WIP 1106.89 1569.98 1944.28 2205.8 601.28
Intangible WIP 0 0 238.25 98.44 0
Investments 506.39 833.25 156.12 219.36 229.27
Loans & Advances 14.31 47.71 36.4 34.88 64.03
Other N/C Assets 8.35 8.35 0 0 0
Current Assets 1993.02 2347.86 2734.38 2859.46 2780.21
Total Assets 4706.05 6075.26 6883.25 7189.04 6052.26
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 764.63 1166.79 1337.74 658.01 345.93
Adjustment 91.48 30.14 92.6 413.35 448.49
Changes in Assets & Liabilities 110.38 -460.39 198.56 -397.3 -10.39
Tax Paid -157.69 -196.79 -240.42 -128.8 -53.78
Operating Cash Flow 808.8 539.75 1388.48 545.26 730.25
Investing Cash Flow -753.67 -821.91 -836.65 -368.72 -460.98
Financing Cash Flow 79.67 166.13 -533.75 -216.64 -261.16
Net Cash Flow 134.8 -116.03 18.08 -40.1 8.11

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 69.61 69.61 69.61 69.61 69.61
alembic limited 28.54 28.54 28.54 28.54 28.54
barkha pranav amin 0.03 0.03 0.03 0.03 0.03
chirayu ramanbhai amin 2.16 2.13 2.13 2.13 2.13
gallup trust (pranav chir... 0.05 0.05 0.05 0.05 0.05
inaaya shaunak amin 0.04 0.04 0.04 0.04 0.04
krupa shaunak amin 0.03 0.03 0.03 0.03 0.03
malika chirayu amin 1.53 1.53 1.53 1.53 1.53
naintara shaunak amin 0.04 0.04 0.04 0.04 0.04
nirayu limited 35.63 35.63 35.63 35.63 35.63
pranav chirayu amin 0.51 0.51 0.51 0.51 0.51
ranvir pranav amin 0.02 0.02 0.02 0.02 0.02
samira pranav amin 0.02 0.02 0.02 0.02 0.02
satori trust (chirayu ram... - 0.03 0.03 0.03 0.03
shaunak chirayu amin 0.51 0.51 0.51 0.51 0.51
udit chirayu amin 0.51 0.51 0.51 0.51 0.51
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 30.39 30.39 30.39 30.39 30.39
dsp midcap fund - 4.23 - - 3.92
investor education and pr... - - 0.75 0.74 0.73
kotak small cap fund 1.74 1.90 1.97 1.97 1.76
life insurance corporatio... 4.33 4.33 4.33 4.33 4.33
llp 0.02 0.02 0.02 0.02 0.02
dsp mutual fund - - 4.48 4.96 -
investor education and pr... 0.70 0.70 - - -
dsp mitual fund 4.21 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Alembic Pharmaceuticals informs about issue of duplicate share certificate16 Apr 2024, 1:40PM Alembic Pharmaceuticals informs about disclosure6 Apr 2024, 12:22PM Alembic Pharmaceuticals informs about press release1 Apr 2024, 5:04PM Alembic Pharma gets tentative USFDA’s nod for breast cancer drug1 Apr 2024, 4:09PM USFDA conducts inspection at Alembic Pharmaceuticals’ Oncology Formulation Facility9 Mar 2024, 3:03PM Alembic Pharmaceuticals informs about updates 9 Mar 2024, 12:29PM Alembic Pharma - Quaterly Results5 Feb 2024, 2:17PM Alembic Pharma - Quaterly Results5 Feb 2024, 2:17PM Alembic Pharma - Quaterly Results5 Feb 2024, 2:17PM Alembic Pharmaceuticals to invest $1.0 million in RIGImmune19 Jan 2024, 2:11PM Alembic Pharmaceuticals informs about disclosure5 Jan 2024, 2:01PM Alembic Pharmaceuticals informs about details of loss of certificate20 Dec 2023, 12:56PM Alembic Pharmaceutical informs about loss of share certificates5 Dec 2023, 5:18PM Alembic Pharmaceuticals informs about investor presentation7 Nov 2023, 4:35PM Alembic Pharmaceuticals reports marginal rise in Q2 consolidated net profit7 Nov 2023, 3:09PM Alembic Pharma - Quaterly Results7 Nov 2023, 1:43PM Alembic Pharma - Quaterly Results7 Nov 2023, 1:43PM Alembic Pharma - Quaterly Results7 Nov 2023, 1:43PM Alembic Pharmaceuticals informs about change in address of RTA21 Oct 2023, 12:15PM Alembic Pharmaceuticals informs about clarification21 Sep 2023, 3:22PM Alembic Pharmaceuticals informs about loss of share certificates20 Sep 2023, 2:39PM Alembic Pharmaceuticals’ arm recalls 82,400 bottles of Tobramycin Ophthalmic Solution in US21 Aug 2023, 4:30PM Alembic Pharmaceuticals informs about press release5 Aug 2023, 4:21PM Alembic Pharmaceuticals informs about outcome of AGM5 Aug 2023, 12:20PM Alembic Pharmaceuticals reports consolidated net profit of Rs 121 crore in Q1FY24 4 Aug 2023, 4:00PM Alembic Pharma - Quaterly Results4 Aug 2023, 1:38PM Alembic Pharma - Quaterly Results4 Aug 2023, 1:38PM Alembic Pharma - Quaterly Results4 Aug 2023, 1:38PM Alembic Pharmaceuticals informs about loss of share certificate29 Jul 2023, 3:21PM Alembic Pharmaceuticals informs about press release3 Jul 2023, 10:03AM Alembic Pharmaceuticals informs about investor meeting1 Jun 2023, 2:59PM Alembic Pharmaceuticals gets EIR for Solid Oral Formulation Facility (F-4) at Vadodara10 May 2023, 9:27AM Alembic Pharmaceuticals informs about audio recording6 May 2023, 11:47AM Alembic Pharma - Quaterly Results5 May 2023, 5:02PM Alembic Pharma - Quaterly Results5 May 2023, 5:02PM Alembic Pharma - Quaterly Results5 May 2023, 5:02PM Alembic Pharmaceuticals informs about details of loss of certificate 5 Apr 2023, 5:17PM Alembic Pharma gets USFDA's final approval for Brimonidine Tartrate Ophthalmic Solution30 Mar 2023, 2:30PM Alembic Pharmaceuticals informs about updates 13 Mar 2023, 9:48AM Alembic Pharmaceuticals completes USFDA’s inspection at Derma Facility 13 Mar 2023, 9:09AM Alembic Pharmaceuticals informs about press release9 Mar 2023, 9:40AM Alembic Pharmaceuticals gets USFDA's tentative approval for Brexpiprazole Tablets9 Mar 2023, 9:18AM Alembic Pharmaceuticals informs about press release8 Mar 2023, 9:56AM Alembic Pharma gets USFDA's final approval for Prazosin Hydrochloride Capsules 8 Mar 2023, 9:21AM Alembic Pharmaceuticals gets USFDA’s final approval for Fluorouracil Injection 6 Mar 2023, 10:38AM Alembic Pharmaceuticals informs about press release6 Mar 2023, 10:29AM Alembic Pharmaceuticals informs about press release1 Mar 2023, 3:23PM Alembic Pharmaceuticals gets USFDA’s final approval for Docetaxel Injection1 Mar 2023, 3:17PM Alembic Pharmaceuticals informs about loss of share certificate23 Feb 2023, 12:38PM Alembic Pharmaceuticals submits analyst meet intimation17 Feb 2023, 4:28PM

Alembic Pharma Stock Price Analysis and Quick Research Report. Is Alembic Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alembic Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Alembic Pharma cash from the operating activity was Rs 730.25 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alembic Pharma has a Debt to Equity ratio of 0.1439 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alembic Pharma , the EPS growth was -36.2100200690665 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alembic Pharma has OPM of 12.8964847543212 % which is a bad sign for profitability.
     
  • ROE: Alembic Pharma have a poor ROE of 7.14566140079529 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Alembic Pharma is Rs 997.5. One can use valuation calculators of ticker to know if Alembic Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Alembic Pharma

Alembic Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the stock analysis page for Alembic Pharmaceuticals Ltd., a prominent pharmaceutical company in India. In this comprehensive analysis, we will delve into various aspects of the company, including its share price, balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders.

Alembic Pharmaceuticals Ltd Share Price

Stay updated on the latest share price of Alembic Pharmaceuticals Ltd. and monitor its performance in the stock market. Ticker provides real-time share price data, allowing you to track the stock's movement and make well-informed investment decisions.

Alembic Pharmaceuticals Ltd Balance Sheet

Gain insights into the balance sheet of Alembic Pharmaceuticals Ltd., an essential financial statement that provides details about the company's assets, liabilities, and shareholders' equity. Utilize ticker premium feature, the DCF Analysis, to calculate the fair value of the company based on its balance sheet.

Alembic Pharmaceuticals Ltd Annual Report

Access the annual reports of Alembic Pharmaceuticals Ltd., which offer a comprehensive overview of the company's performance, achievements, and strategic initiatives. These reports are conveniently available for download on Ticker, enabling you to analyze the company's financials in detail.

Alembic Pharmaceuticals Ltd Dividend

Stay informed about the dividend payouts of Alembic Pharmaceuticals Ltd. to its shareholders. Explore the history of dividends, dividend yield, and dividend payment dates. Ticker pre-built screening tools can assist in identifying stocks with consistent and attractive dividend payouts.

Alembic Pharmaceuticals Ltd Quarterly Results

Analyze Alembic Pharmaceuticals Ltd.'s quarterly results, including revenue, profit, and key financial metrics. Utilize ticker premium features, such as BVPS Analysis, Earnings multiple approach, and DuPont analysis, to gain a deeper understanding of the company's financial performance.

Alembic Pharmaceuticals Ltd Stock Price

Track the historical stock price of Alembic Pharmaceuticals Ltd. using our interactive price charts. Ticker provides customizable charts with various timeframes, technical indicators, and overlays, enabling you to evaluate the stock's performance effectively.

Alembic Pharmaceuticals Ltd Price Chart

Analyze the stock price movements of Alembic Pharmaceuticals Ltd. through ticker user-friendly price chart. Customize the chart to view key trends, patterns, and support/resistance levels that can assist you in making well-informed investment decisions.

Alembic Pharmaceuticals Ltd News

Stay up to date with the latest news and developments related to Alembic Pharmaceuticals Ltd. Ticker platform curates news articles to keep you informed about the company's performance, industry trends, and market dynamics.

Alembic Pharmaceuticals Ltd Concall Transcripts

Explore the concall transcripts of Alembic Pharmaceuticals Ltd., which provide detailed records of the company's conference calls with analysts and investors. Through these transcripts, you can gain valuable insights into the company's future plans, strategies, and overall outlook.

Alembic Pharmaceuticals Ltd Investor Presentations

Access the investor presentations of Alembic Pharmaceuticals Ltd., which offer a comprehensive overview of the company's business model, growth prospects, and investment opportunities. These presentations provide valuable insights into the company's operations and strategic initiatives.

Alembic Pharmaceuticals Ltd Promoters

Learn about the key promoters of Alembic Pharmaceuticals Ltd., the individuals or entities who have played a significant role in establishing and expanding the company. Gain insights into their background, contributions, and shareholding patterns.

Alembic Pharmaceuticals Ltd Shareholders

Understand the shareholder base of Alembic Pharmaceuticals Ltd. and the distribution of ownership among various categories of investors. Analyze the institutional and retail investor participation to gauge market sentiment towards the stock.

Experience the power of comprehensive stock analysis with Alembic Pharmaceuticals Ltd. Ticker provides a range of pre-built screening tools, downloadable annual reports, and real-time stock data to assist you in making informed investment decisions. Start exploring today!

Read More
X